IBM Retirement Fund lessened its stake in Humana Inc (NYSE:HUM) by 6.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,460 shares of the insurance provider’s stock after selling 163 shares during the quarter. IBM Retirement Fund’s holdings in Humana were worth $705,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of HUM. Keybank National Association OH raised its stake in shares of Humana by 1.7% in the fourth quarter. Keybank National Association OH now owns 2,259 shares of the insurance provider’s stock valued at $647,000 after buying an additional 37 shares during the period. Proficio Capital Partners LLC raised its stake in shares of Humana by 81.4% in the fourth quarter. Proficio Capital Partners LLC now owns 107 shares of the insurance provider’s stock valued at $31,000 after buying an additional 48 shares during the period. ClariVest Asset Management LLC raised its stake in shares of Humana by 9.5% in the fourth quarter. ClariVest Asset Management LLC now owns 635 shares of the insurance provider’s stock valued at $182,000 after buying an additional 55 shares during the period. Archford Capital Strategies LLC raised its stake in shares of Humana by 2.7% in the fourth quarter. Archford Capital Strategies LLC now owns 2,376 shares of the insurance provider’s stock valued at $681,000 after buying an additional 63 shares during the period. Finally, Kovack Advisors Inc. raised its stake in shares of Humana by 3.4% in the fourth quarter. Kovack Advisors Inc. now owns 1,958 shares of the insurance provider’s stock valued at $561,000 after buying an additional 64 shares during the period. Institutional investors own 94.51% of the company’s stock.
Several analysts have issued reports on HUM shares. JPMorgan Chase & Co. upgraded Humana from a “neutral” rating to an “overweight” rating and set a $283.00 target price on the stock in a research note on Thursday, December 20th. Citigroup reduced their price target on Humana from $397.00 to $362.00 and set a “buy” rating for the company in a research report on Thursday, February 7th. Cowen upgraded Humana from a “market perform” rating to an “outperform” rating and set a $275.02 price target for the company in a research report on Friday, January 11th. Cantor Fitzgerald reiterated a “hold” rating and issued a $325.00 price target on shares of Humana in a research report on Wednesday, January 2nd. Finally, Stephens assumed coverage on Humana in a research report on Monday, January 14th. They issued an “overweight” rating and a $336.00 price target for the company. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $355.06.
Shares of HUM traded up $3.39 during midday trading on Friday, reaching $266.00. The stock had a trading volume of 1,215,842 shares, compared to its average volume of 1,174,853. Humana Inc has a 12-month low of $259.13 and a 12-month high of $355.88. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $36.08 billion, a P/E ratio of 18.28, a PEG ratio of 1.10 and a beta of 0.94.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 6th. The insurance provider reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.12. Humana had a return on equity of 19.64% and a net margin of 2.96%. The firm had revenue of $14.17 billion during the quarter, compared to analysts’ expectations of $14.04 billion. During the same period in the prior year, the business earned $2.06 EPS. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, equities research analysts predict that Humana Inc will post 17.49 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be issued a $0.55 dividend. This is a boost from Humana’s previous quarterly dividend of $0.50. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date of this dividend is Thursday, March 28th. Humana’s dividend payout ratio is presently 3.44%.
In other news, insider Christopher H. Hunter sold 15,586 shares of the business’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $305.24, for a total value of $4,757,470.64. Following the completion of the sale, the insider now owns 28,100 shares of the company’s stock, valued at approximately $8,577,244. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Roy A. Beveridge sold 8,278 shares of the business’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total value of $2,542,670.48. Following the completion of the sale, the insider now directly owns 12,409 shares of the company’s stock, valued at approximately $3,811,548.44. The disclosure for this sale can be found here. 0.54% of the stock is currently owned by corporate insiders.
About Humana
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
